Company news

Seres Therapeutics, Inc. news in 2024

Seres Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

December 8, 2024

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

November 12, 2024

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

September 29, 2024

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

September 25, 2024

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

September 11, 2024

Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

August 12, 2024

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

August 5, 2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2024

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

June 5, 2024

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

May 5, 2024

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

April 8, 2024

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

March 4, 2024

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

February 25, 2024

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

January 8, 2024

Calls in 2024

Decks in 2024